Eugit Therapeutics

Summer 2022Active

Enabling Tissue Targeting of Therapies

Save

Eugit Therapeutics

Summer 2022Active

Enabling Tissue Targeting of Therapies

Save

Company details

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.

Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Location

San Francisco, CA, USA; South San Francisco, CA, USA

Founded

Unknown

Request the Eugit Therapeutics report.

Eugit Therapeutics has no report yet. Sign in with your email to request one.